SAINT LAURENT, QUEBEC--(MARKET WIRE)--Sep 10, 2007 -- IntelGenx Technologies Corp. (OTC BB:IGXT.OB - News) ("IntelGenx"), a drug delivery company, announced today that its proprietary SL tablet technology will be included in the Phase 1 Study of CAT 310, a potential new treatment for neuropathic pain being developed by Cannasat Therapeutics Inc., a Canada-based early stage pharmaceutical R&D company.
